-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Downgrades Ventyx Biosciences to Neutral, Lowers Price Target to $14

Benzinga·01/08/2026 12:42:50
Listen to the news
UBS analyst Michael Yee downgrades Ventyx Biosciences (NASDAQ:VTYX) from Buy to Neutral and lowers the price target from $20 to $14.